Rocket Pharmaceuticals Inc (NAS:RCKT)
$ 22.23 0.3 (1.37%) Market Cap: 2.02 Bil Enterprise Value: 1.69 Bil PE Ratio: 0 PB Ratio: 4.56 GF Score: 39/100

Rocket Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 18, 2023 / 12:45PM GMT
Release Date Price: $19.03 (-0.52%)
Gil Blum
Needham & Company, LLC - Analyst

Good morning, everyone, and thank you for joining us this morning at the Needham & Company conference. My name is Gil Blum and I'm a senior biotech analyst here at Needham & Company covering the gene therapy space.

It is my pleasure to have with me today Dr. Gaurav Shah, Rocket Pharma's CEO. (Conference Instructions)

Questions & Answers

Gil Blum
Needham & Company, LLC - Analyst

So maybe it's a good place to start as an introduction. I mean, investors have become kind of sanguine on gene therapy as of late. So do you think that potential for larger population drug approvals -- there is a filing for SRP-9001 in DMD and Exa-Cel in SCT, and your own drug in Danon disease. Do you think that could change sentiment?

Gaurav Shah
Rocket Pharmaceuticals, Inc. - CEO

Good to see you again. Thanks for having us this year. I think it will potentially change sentiment. I think there was a time when gene therapy was a platform that was very exciting,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot